# The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

> **NCT02211209** · PHASE3 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 67 (actual)

## Conditions studied

- Familial Chylomicronemia Syndrome

## Interventions

- **DRUG:** Volanesorsen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02211209
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-12-19
- **Final completion:** 2017-03-28
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2022-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02211209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02211209, "The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT02211209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*